An Observational Cohort Study to Describe and Compare the Use of Darolutamide, Enzalutamide and Apalutamide and How Well These Work in Men With Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) in Real World Settings

CompletedOBSERVATIONAL

Enrollment

1,375

Participants

Timeline

Start Date

August 31, 2023

Primary Completion Date

June 28, 2024

Study Completion Date

October 28, 2024

Conditions

Non-metastatic Castration-resistant Prostate Cancer

Interventions

DRUG

Apalutamide

Decision by the treating physician

DRUG

Darolutamide (BAY 1841788)

Decision by the treating physician

DRUG

Enzalutamide

Decision by treating physician

Trial Locations (1)

Bayer, Whippany